Program Agenda

Thursday, October 20, 2022
2:00 – 9:00 PM	REGISTRATION

Friday, October 21, 2022
7:00 AM – 5:00 PM	REGISTRATION
8:00 – 8:10 AM	OPENING CEREMONY Mitchell S. Cairo, MD, Chair, USA
8:10 – 9:00 AM	ANGELO ROSOLEN, MD MEMORIAL LECTURE
8:10 – 8:15 AM	INTRODUCTION Marta Pillon, MD, Italy, & Lara Mussolin, PhD, Italy
8:15 – 8:20 AM	INTRODUCTION FOR CATHERINE PATTE, MD, FRANCE Laurence Brugieres, MD, France
8:20 – 8:35 AM	IN B-CELL LYMPHOMA: SUCCESSFUL COLLABORATION BETWEEN EUROPE AND NORTH AMERICA. WHAT KIND OF PARTNERSHIP WITH AFRICA? Catherine Patte, MD, France
8:35 – 8:40 AM	INTRODUCTION FOR SHERRIE PERKINS, MD, PhD, USA Megan Lim, MD, PhD, USA
8:40 – 8:55 AM	THE ROLE OF PATHOLOGY IN SHAPING TREATMENT FOR PEDIATRIC NHL: A 25 YEAR PERSPECTIVE Sherrie Perkins, MD, PhD, USA
9:00 – 10:45 AM	PLENARY SESSION I – MATURE B-CELL NHL Moderators: Stanton Goldman, MD, USA & Veronique Minard-Colin, MD, PhD, France
9:00 – 9:20 AM	RITUXIMAB IMPROVES OUTCOME IN CHILDREN AND ADOLESCENTS WITH ADVANCE STAGE MATURE B-NHL Veronique Minard-Colin, MD, PhD, France
9:20 – 9:40 AM	RITUXIMAB LOWERS THE CHEMOTHERAPY BURDEN IN CHILDREN AND ADOLESCENTS WITH LIMITED STAGE MATURE B-NHL Stanton Goldman, MD, USA
9:40 – 10:00 AM	MUTATIONAL LANDSCAPE IN PEDIATRIC BURKITT-LIKE LYMPHOMA (BLL) WITH 11q ABERRATION Reiner Siebert, MD, Germany
10:00 – 10:10 AM	Non-Germinal Center B-cell Subtype of Pediatric Diffuse Large B-Cell Lymphoma in Japan: A Multi-Case Analysis D. Hori1,², R. Kobayashi^1,2, A. Nakazawa^1,3, H. Iwafuchi^1,4, W. Klapper⁵, t. Osumi^1,6, N. Fujita^1,7, T. Mitsui^1,8, Y. Koga^1,9, T. Mori^1,10, R. Fukano^1,11, K. Ohki^1,12, M. Kamei^1,13, T. Mori^1,14, M. Tanaka^1,15, T. Tsuchimochi^1,16, K. Moriya^1,17, K. Tao^1,18, A. Kada¹⁹, M. Sekimizu^1,20
10:10 – 10:20 AM	BCR Expression in Burkitt Lymphoma: New Insight in Mutational Landscape M. Siciliano¹, M. Vannucchi¹, S. Tornambè¹, M. Granai², F. Arcuri¹, E. Sorrentino^1, V. Mancini¹, N. de Leone¹, S. Lazzi^1, R. Siebert³, L. Leoncini¹, C. Bellan*¹
10:20 – 10:30 AM	Noncoding RNAs in Burkitt Lymphoma C. López^1,2,3, H. Kretzmer^4,5,6,7, E. Chteinberg¹, S. H Bernhart^4,5,6, S. Glaser¹, P. Patil¹, O. Ammerpohl¹, ICGC MMML-Seq Consortium, B. Burkhardt⁸, M. Schlesner^9,10, S. Hoffmann^4,5,6,11, R. Siebert^1,2
10:30 – 10:45 AM	PANEL DISCUSSION AND QUESTIONS & ANSWERS
10:45 – 11:00 AM	COFFEE BREAK
11:00 – 12:45 PM	PLENARY SESSION II – LYMPHOMA TRANSLATIONAL BIOLOGY (DEDICATED IN MEMORY TO WARREN SANGER, PhD) Moderators: Lara Mussolin, PhD, Italy & Wolfram Klapper, MD, Germany
11:00 – 11:20 AM	PRECISION MEDICINE IN ADULT LYMPHOMA Keynote Speaker # 1– Louis Staudt, MD, PhD, USA
11:20 – 11:40 AM	EMERGING EPIGENETIC MODULATING THERAPIES IN NHL Ari Melnick, MD, USA
11:40 – 12:00 PM	INTEGRATIVE GENOMIC ANALYSIS OF PEDIATRIC T-LYMPHOBLASTIC LYMPHOMA Birgit Burkhardt, MD, PhD, Germany
12:00 – 12:10 PM	ALK+ ALCL Evades Immune Surveillance through NPM-ALK-Driven Epigenetic Repression CD48 R. Wu1, A. Sahasrabuddhe¹, E. Ivan², T. Shaw³, C. Mullighan⁴; V. Leventaki⁴, K. Elenitoba-Johnson1, M. Lim¹
12:10 – 12:20 PM	Burkitt Lymphoma and High-Grade B-Cell Lymphoma with 11q Aberrations Share a Transcriptional Profile Resembling a Subpopulation of Early Dark Zone Cells Gioia Di Stefano^1,2,3, Emil Chteinberg³, Henry Loeffler-Wirth⁴, Sina Hillebrecht³, Rabea Wagener³, Dmitriy Abramov⁵, Birgit Burkhardt⁶, Abner Louissant⁷, Heike Horn¹³, Anja Mottok^3,8, Ilske Oschlies⁹, Wolfram Klapper⁹, Kristian Schafernak¹⁰, Yanming Zhang¹¹, Coral Del-Val^3,12, Andreas Rosenwald⁸, Hans Binder⁴, German Ott¹³, Lorenzo Leoncini², Reiner Siebert³
12:20 – 12:30 PM	Burkitt Lymphoma and High-Grade B-Cell Lymphoma with 11q Aberrations Share a Transcriptional Profile Resembling a Subpopulation of Early Dark Zone Cells Gioia Di Stefano^1,2,3, Emil Chteinberg³, Henry Loeffler-Wirth⁴, Sina Hillebrecht³, Rabea Wagener³, Dmitriy Abramov⁵, Birgit Burkhardt⁶, Abner Louissant⁷, Heike Horn¹³, Anja Mottok^3,8, Ilske Oschlies⁹, Wolfram Klapper⁹, Kristian Schafernak¹⁰, Yanming Zhang¹¹, Coral Del-Val^3,12, Andreas Rosenwald⁸, Hans Binder⁴, German Ott¹³, Lorenzo Leoncini², Reiner Siebert³
12:30 – 1:00 PM	PANEL DISCUSSION AND QUESTIONS & ANSWERS (non-CME event)

1:00 – 1:45 PM	LUNCH SYMPOSIUM – The ALLternative: Confronting ALL With ASPARLAS As Part Of A Multi-Agent Chemotherapy Regimen – Supported by Servier Pharmaceuticals

2:15 – 4:15 PM	PLENARY SESSION III – RARE NON-HODGKIN LYMPHOMA Moderators – Ana Xavier, MD, USA & Yonghong Zhang, MD, PhD, China
2:15 – 2:35 PM	NEW THERAPEUTIC APPROACHES TO ADVANCED NK/T-CELL LYMPHOMA Ana Xavier, MD, USA
2:35 – 2:55 PM	PEDIATRIC-TYPE FOLLICULAR LYMPHOMA (PTFL) and MARGINAL ZONE LYMPHOMA (MZL) Karin Mellgren, MD, Sweden
2:55 – 3:15 PM	EBV, HLH AND THE ASSOCIATED SPECTRUM OF T/NK-CELL LYMPHOPROLIFERATION Nader El-Mallawany, MD, USA
3:15 – 3:25 PM	EBV-Driven Lymphoid Neoplasms Associated with ALL Maintenance Therapy: An International Observational Study S. Elitzur1, A.Vora² B. Burkhardt³, H. Inaba⁴, A. Attarbaschi⁵, A. Baruchel⁶, G. Escherich⁷, B. Gibson⁸, H. Liu⁹, M. Loh¹⁰, A. Moorman¹¹, A. Moricke¹², R. Pieters¹³, A. Uyttebroeck¹⁴, S. Baird¹⁵, J. Bartram², M. Ben-Harosh¹⁶, Y. Bertrand¹⁷, T. Buitenkamp¹⁸, K. Caldwell¹⁹, R. Drut²⁰, A. Geerlinks²¹, J. Grainger²², S. Haouy²³, N. Heaney²⁴, M. Huang²⁵, D. Ingham²⁶, Z. Krenova²⁷, M. Kuhlen²⁸, T. Lehrnbecher²⁹, A. Manabe³⁰, F. Niggli³¹, C. Paris³², S. Revel-Vilk³³, P. Rohrlich³⁴, B. Sandeep³⁵, M. Sinno³⁶, T. Szczepanski³⁷, M. Tamesberger³⁸, R. Warrier³⁹, M. Wolfl⁴⁰, R. Nirel⁴¹, S. Izraeli¹, A. Borkhardt⁴², K. Schmiegelow⁴³
3:25 – 3:35 PM	The Challenge of Prospective Distinction Between Non-Neoplastic Versus Neoplastic EBV-Associated HLH N. Gulati,^1,2 O. Eckstein,^1,2 J. Agrusa,^1,2 K. Kamda^r,1,2 R. Rouce,^1,2 C. Curry,^3,4 K. Fisher,^3,4 L. Forbes,^3,5 A. Grim^,2,6 E. Peckham-Gregory,^1,2,7 K. McClain,^1,2 C. Allen^,1,2 N. El-Mallawany^1,2
3:35 – 3:45 PM	Survival of Patients with Extranodal NK-cell Lymphoma in the United States A. Xavier¹, N. El-Mallawany², M. Ehrhardt³, L. Costa MD⁴, M. Cairo^5,6,7,8,9

3:55 – 4:15 PM	PANEL DISCUSSION AND QUESTIONS & ANSWERS
4:15 – 4:30 PM	COFFEE BREAK
4:30 – 6:15 PM	PLENARY SESSION IV – IMMUNOLOGY, CELL THERAPY AND HEMATOPOIETIC STEM CELL TRANSPLANTATION Moderators: Amos Burke, MD, UK & Wilhelm Woessmann, MD, Germany
4:30 – 4:50 PM	PAST, PRESENT AND FUTURE OF CAR T-CELLS Keynote Speaker #2 – Carl June, MD, USA
4:50 – 5:10 PM	IMMUNE RESPONSE TO ALK IN ALK-POSITIVE LYMPHOMAS Wilhelm Woessmann, MD, Germany
5:10 – 5:30 PM	NOVEL IMMUNOTHERAPEUTICS Mitchell S. Cairo, MD, USA
5:30 – 5:40 PM	CD72 Nanobody CAR-T Cells Have Potent Antitumor Efficacy in B Cell Malignancies W.Temple1, M. Nix², G. Wicaksono², D. Wang³, P. Phojanakong³, V. Steri³, B. Hann³, M. Hermiston¹, A. Wiita²
5:40 – 5:50 PM	Impact of Rituximab on Immune Status Following Therapy in Children and Adolescents with High-Risk Mature B-Cell Non-Hodgkin Lymphoma: Results of the Inter-B-NHL Ritux 2010 Trial S. Alexander¹, A. Aupérin², S. Bomken³, M. Csoka⁴, B. Kazanowska⁵, A. Chiang⁶, M. Andrés Moreno ⁷, A. Uyttebroeck⁸, A. Burke⁹, J. Zsiros¹⁰, M. Pillon¹¹, C. Bollard¹², D. Barkauskas¹³, K. Wheatley¹⁴, C. Patte¹⁵, T. Gross¹⁶, V. Minard-Colin¹
5:50 – 6:00 PM	EPSTEIN-BARR Virus Orchestrate the Tumor Microenvironment of Burkitt Lymphoma M. Siciliano¹, S. Tornambè¹, M. Del Corvo², M. Granai³, L. Mundo⁴, M. Sapienza², F. Arcuri¹, V. Mancini¹, R. Santi⁵, G. Di Stefano⁵, T. Marafioti⁶, G. Ott⁷, R. Siebert⁸, L. Quintanilla Fend³, F. Fend³, S. Pileri², L. Leoncini*¹, S. Lazzi¹
6:00 – 6:15 PM	PANEL DISCUSSION AND QUESTIONS & ANSWERS
6:15 – 7:45 PM	WELCOME RECEPTION & POSTER VEIWING (ALL REGISTRANTS)

Saturday, October 22, 2022
7:00 AM – 5:00 PM	REGISTRATION
7:00 – 7:45 AM	BREAKFAST SYMPOSIUM –Understanding Tumor Lysis Syndrome Associated with Hyperuricemia in an Evolving Pediatric Cancer Treatment Landscape, Mitchell S. Cairo, MD, USA – Supported by Sanofi
7:45 – 8:30 AM	MEET THE PROFESSORS (Choose One Session)(non-CME event)
Session 1	ANAPLASTIC LARGE CELL LYMPHOMA (ALCL): THE EUROPEAN PERSPECTIVE Laurence Brugieres, MD, France
Session 2	NK/T CELL LYMPHOMAS: THE JAPANESE PRESPECTIVE Ritsuro Suzuki, MD, PhD, Japan
Session 3	MINIMAL DISSEMINATED DISEASE AND MINIMAL RESIDUAL DISEASE DETECTION Christine Damm-Welk, PhD, Germany
Session 4	MOLECULAR-BASED THERAPEUTIC APPROACHES TO LANGERHANS CELL HISTIOCYTOSIS Carl Allen, MD, PhD, USA

8:30 – 10:15 AM	PLENARY SESSION V – ADOLESCENT AND YOUNG ADULT HODGKIN AND NON-HODGKIN LYMPHOMA Moderators – Owen Smith, MA, MB, Ireland & Michael Link, MD, USA
8:30 – 8:50 AM	OUTCOME OF AYA vs CHILDHOOD NHL: THE IRISH EXPERIENCE Owen Smith, MA, MB, Ireland
8:50 – 9:10 AM	OUTCOME OF AYA PATIENTS WITH MATURE B-CELL LYMPHOMA TREATED ON PEDIATRIC INSPIRED PROTOCOLS Sarah Alexander, MD, Canada
9:10 – 9:30 AM	PATHOBIOLOGY AND NOVEL APPROACHES TO PRIMARY MEDIASTINAL B-CELL LYMPHOMA (PMBL) Lisa Giulino-Roth, MD, USA
9:30 – 9:40 AM	Childhood and Adolescent Hodgkin Reed-Sternberg Cells Demonstrate Unique Gene Expression Signature Consistent with Oncogenic-Induced Senescence J. Agrusa¹, H. Lin¹, H. Abhyankar¹, J. Velazquez, E. Fattah¹, B. Scull¹, N. Ozuah¹, O. Eckstein¹, N. El-Mallawany¹, N. Gulati1, J. Lubega¹, T. Horton¹, K. Kamdar¹, K. McClain¹, C. Man¹, C. Allen¹.
9:40 – 9:50 AM	Excellent Outcome of Children/Adolescents with Primary Mediastinal Large B Cell Lymphoma Treated with LMB-Based Chemotherapy with Rituximab M. Dourthe^1,2 , A. Phulpin ³ , A. Auperin⁴, M. Couec ⁵, P. Dartigues⁶, S. Ducassou⁷, N. Garnier⁸ , S. Haouy⁹, T. Leblanc¹, A. Lambilliotte¹⁰, A. Leruste¹¹, A. Jourdain¹², A. Spiegel¹³, C. Rigaud¹⁴, M. Simonin¹⁵, J. Bonneau¹⁶, A. Verschuur¹⁷, G. Plat¹⁸, M. Poirée¹⁹, N. Buchbinder²⁰, J. Landman-Parker¹⁵, C. Patte¹⁴, v. Minard-Colin^14,21
9:50 – 10:00 AM	Reducing the Burden of Oncology Chemoradiotherapy And Radiation Exposure from Diagnostic Imaging by Utilizing Targeted Immunotherapy in Children, Adolescents and Young Adults with Lymphoma (RADICAL, Hodgkin Lymphoma Cohort). J. Hochberg¹*, A. Xavier², A. Audino³, M. Barth⁴, R. Miles⁵, S. Kahwash⁶, S. Voss⁷, S. Braniecki³, C. Moorthy⁸, S. Armenian⁹, M. Ehrhardt¹⁰, M. Lim¹¹, L. Harrison¹, S. Goldman¹², M. Cairo^{1,13,14,15,16}
10:00 – 10:15 AM	PANEL DISCUSSION AND QUESTIONS & ANSWERS
10:15 – 10:30 AM	COFFEE BREAK
10:30 – 12:30 PM	PLENARY SESSION VI – SURVIVORSHIP AND LATE EFFECTS Moderators – Matthew Ehrhardt, MD, USA & Jessica Hochberg, MD, USA
10:30 – 10:50 AM	LATE HEALTH OUTCOMES IN CHILDREN AND ADOLESCENTS WITH MATURE B-CELL NHL Matthew Ehrhardt, MD, USA
10:50 – 11:10 AM	SECOND MALIGNANCY AFTER TREATMENT IN CHILDREN AND ADOLESCENTS WITH NHL Marta Pillon, MD, Italy
11:10 – 11:30 AM	FERTILITY AND SEXUALITY IN CHILDHOOD AND ADOLESCENT NHL SURVIVORS TBD
11:30 – 11:40 AM	Long Term Pulmonary and Cardiac Function Affection among Non-Hodgkin’s Lymphoma Survivors A. Ayad1, A. Hamoda^{1, 2}, R. Khedr^{1, 2}, N. Elnabarawy³, E. Rifky³, T. Diab⁴, L. Leihmann ⁵, A. El-Haddad


11:40 – 12:10 PM	PANEL DISCUSSION AND QUESTIONS & ANSWERS (non-CME event)
12:15 – 12:30 PM	PICK UP LUNCH
12:30 – 1:15 PM	LUNCH SYMPOSIUM –The Only Recombinant ERWINIA ASPARAGINASE Approved for the T Treatment of ALL/LBL, Scott Howard, MD, MSc -Supported by Jazz Pharmaceuticals

1:45 – 3:45 PM	PLENARY SESSION VII – NOVEL THERAPEUTICS Moderators – Lara Mussolin, PhD, Italy & Carl Allen, MD, PhD, USA
1:45 – 2:05 PM	ALK INHIBITOR THERAPY IN ALCL Masahiro Sekimizu, MD, Japan
2:05 – 2:25 PM	TARGETING THE P13K/AKT/MTOR PATHWAY Matthew Barth, MD, USA
2:25 – 2:45 PM	EXOSOMES IN NHL OF CHILDHOOD: SMALL VESICLES WITH A GREAT POWER Lara Mussolin, PhD, Italy
2:45 – 2:55 PM	Obinutuzumab (GA101) vs. Rituximab Significantly Enhances Cell Death, Antibody-Dependent Cytotoxicity and Improves Overall Survival Against CD20+ Primary Mediastinal B-Cell Lymphoma (PMBL) in a Xenograft NOD-Scid IL2Rgnull (NSG) Mouse Model: A Potential Targeted Agent in the Treatment of PMBL Y. Chu1, A. Awasthi¹, S. Lee^1,2, D. Edani¹, C. Yin¹, J. Hochberg¹, T. Shah¹, T. Chung⁶, J. Ayello¹, C. van de Ven¹, C. Klein⁷, D. Lee⁸, M. Cairo^1,2,3,4,5,
2:55 – 3:05 PM	Resistance to Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors (TKIs) in Paediatric Anaplastic Large Cell Lymphoma (ALCL) L. Hare^1,2, N. Prokoph¹, A. Burke², S. Turner^1,3
3:35 – 3:15 PM	Brigatinib Shows Preclinical Promise for Aggressive Relapsed/Refractory AK=LK-Positive ALCL J. Matthews¹^, N. Prokoph^1, R. Trigg¹, I. Montes-Mojarro², F. Fend², L. Kenner^4-7, B. Geoerger^8,9, R. Johnston¹⁰, M. Murray^1,3, L. Brugières⁸, A. Burke³, Suzanne D Turner^1,11,‡
3:15 – 3:25 PM	A Novel Cytokine-Antibody Fusion Protein, N-820, to Enhance the Functions of Ex-Vivo Expanded Natural Killer Cells against Burkitt Lymphoma Y. Chu^1, G. Nayyar¹, N. Su¹, J. Rosenblum¹, P. Soon-Shiong², J. Lee², J. Safrit³, M. Barth⁴, D. Lee⁵, M. Cairo^1,6,7,8,9
3:25 – 3:45 PM	PANEL DISCUSSION AND QUESTIONS & ANSWERS
3:45 – 4:00 PM	COFFEE BREAK
4:00 – 6:00 PM	PLENARY SESSION VIII – POSTER DISCUSSION Moderators – Paul Galardy, MD, USA; Birgit Burkhardt, MD, PhD, Germany; Laurence Brugieres, MD, France; & Itziar Salaverria, PhD, Spain
	WORLD WIDE EXPERIENCES Discussant: Itzar Salverria, PhD Mature B Cell Non-Hodgkin Lymphoma Treatment and Results in a Retrospective Cohort of Children and Adolescents Treated Between 2016 and 2020 in Latin G. Chantada^1-2, M. Schelotto¹, A. Braz³, M. Soria⁴, F. Luisi⁵, C. Salgado⁶, C. Montilva⁷, C. Garrido⁸, P. Rezende⁹, D. Flores¹, P. Domínguez¹⁰, A. Peña¹⁰, M. Metzger² 18F-FDG-PET/CT in the Assessment of Bone Marrow Involvement in Pediatric Non-Hodgkin Lymphoma-A Single Center Experience M. Siri¹, H. Rosenfeld-Keidar¹, M. Yaffe-Ornstein¹, R. Shukrun¹, R. Elhasid¹ Pediatric Low Grade Lymphoma: A Report from A Single N.Kurucu¹, T. Kutluk¹, A. Sağlam², B. Oğuz³, M. Haliloğlu³, B. Aydın¹, B. Yalçın¹, A. Varan¹, A. Üner² Summary of the Mid-Term efficacy of China Net Children Lymphoma (CNCL) -Mature B-Cell Lymphoma-2017 Regimen in the Treatment of Pediatric Burkitt’s Lymphoma Z. Meng¹ B-cell NHL Relapses in PPLLSG Patients in Years 2004-2021 E. Latos-Grażyńska¹, D. Przystupski¹, B. Kazanowska¹ Clinical Spectrum of Precursor B-Cell Lymphoblastic Malignancies: A Large Cohort Study of 364 Pediatric Patients E. Kroeze¹, M. Bakker¹, J. Boer¹, M. Hagleitner, B. Burkhardt², L. Padilla², T. Mori³, A. Attarbaschi⁴, J. Verdú-Amorós⁵, M. Pillon⁶, L. Anderzhanova⁷, E. Kabíčková⁸, A. Chiang⁹, R. Kebudi¹⁰, K. Mellgren¹¹, J. Lasic¹², J. Jazbec¹³, J. Meijerink¹, A. Beishuizen^1,14, J. Loeffen¹, on behalf of the European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL) and the International Berlin-Frankfurt-Münster (i-BFM) Study Group. LYMPHOMA BIOLOGY Discussant: Paul Galardy, MD Genome-Wide Genomic Abnormalities and Functional Essential Genes in Burkitt Lymphoma: A Systematic Review and Meta-Analysis P. Zhou^1,2,3^, M. Zaka^1,2,3, A. Newman^1,2,3, A. Blain^3, N.Hajduga^1,2, S. Bomken^3,4, C. Bacon^3,5, V. Rand^1,2,3* Characterization of IG-MYC-Breakpoints and their Application for Quantitative Minimal Disease Monitoring in High-Risk Pediatric Burkitt-Lymphoma and –Leukemia C. Damm-Welk¹, P. Möker^1, U. Stad^t2, M. Zimmermann³, M. Alawi^4, S. Mueller⁵, J. Finger^5, F. Knörr1^,6, A. Riquelme^1, I. Oschlies^7, W. Klapper^7, J. Bradtke⁸, B. Burkhardt⁵, W. Woessmann¹ Single-cell Transcriptomic Analysis of Pediatric Burkitt Lymphoma Reveals Intra-Tumor Heterogeneity C. Corinaldesi^1,, I. Gallingani^2,3, A. Holmes1, F. Lovisa^2,3, E. Carraro^2, M. Pillon^2, R. Dalla-Favera^1,4,5, K. Basso^1,4, L. Mussolin^2,3. Blocking the BCL10-MALT1 Interaction in Diffuse B-Cell Lymphoma L. Maurer^1, H. Kang^1, M. Smyers^1, L. Klei¹ J. Cheng^1, M. Trotta^1, D. Hu^1, P. Ekambaram^1, M. Murai^2, Z. Nikolovska-Coleska^2, B. Chen^1, P. Lucas^1, L. McAllister-Lucas¹ Rituximab Clearance in Pediatric Patients with Mature Aggressive B-Cell Non-Hodgkin Lymphoma I. Tölle¹^, C. Lanvers-Kaminsky^1, M. Bethke^1, G. Randau^1, M. Rolfing^1, A. Tann^1, M. te Vrugt^1, K. Mellgren^2, S. Müller^1, B. Burkhardt¹ Immunology, Cell therapy, HSCT Discussant: Birgit Burkhardt, MD, PhD Safety Profile of Rituximab in Initial Treatment of Children and Adolescents with Mature Aggressive B-NHL J. Finger1, R. Schmidt^2, K. Mellgren^3, M. Gunnes^4, P. Huttunen^5, E. Kabíčková^6, A. Attarbaschi^7, F. Ceppi^8, P. Wehner^9, S. Müller^1, B. Burkhardt¹ Safety and Tolerability of Myeloablative Conditioning and Autologous Stem Cell Transplantation Followed by Polatuzumab Vedotin (PV) Immunoconjugate Therapy in Patients with B-Cell Non-Hodgkin Lymphoma A. Gardenswartz^1, K. Seiter^4, J. Hochberg^1, E. Morris^1, L. Harrison^1, Y. Chu^1, J. Basso1, P. Gerard^2, H. Islam^3, J. Ayello^1, M. Cairo^1,2,3,4,5,6* ¹Department of Pediatrics, New York Medical College, Valhalla, NY, USA; ²Department of Radiology, New York Medical College, Valhalla, NY, USA; ³Department of Pathology, New York Medical College, Valhalla, NY, USA; ⁴Department of Medicine, New York Medical College, Valhalla, NY, USA; ⁵Department of Microbiology and Immunology, New York Medical College, Valhalla, NY, USA; ⁶Department of Cell Biology and Anatomy, New York Medical College, Valhalla, NY, USA Combined Bortezomib and Venetoclax Targets the Pro-Survival Functions of Latent Viral Proteins in Epstein-Barr Virus-Driven Lymphoproliferative Diseases A. Chiang^1, K. Tam^1, R. Au-Yeung² A Multicenter Pilot Study Using Induction Chemo-Immunotherapy Followed by Consolidation with Reduced Toxicity Conditioning and Allogeneic Stem Cell Advanced Stage Mature Non-Anaplastic T/NK-cell lymphoma/leukemia in Children, Adolescent, and Young Adults (CAYA) A. Xavier1; L. Harrison^2; R. Miles3; S. Voss^4; M. Lim^5; M.Cairo^2,6,7,8,9 PTLD* Discussant: Thomas Gross, MD, PhD Outcome of Children Treated for Recurrent Epstein-Barr virus (EBV)-associated Post- Transplant Lymphoproliferative Disease (PTLD) K. Devine¹, A. Seif¹, B. Laskin¹, A. Reilly¹ Characteristics and Outcome of Post-Transplant Lymphoproliferative Disorders after Solid Organ Transplantation V. Vergote^1, A. Uyttebroeck², C. Deroose³, S. Fieuws⁴, W. Laleman⁵, B. SPRANGERS⁶, J. Van Cleemput⁷, G. Verhoef¹, R.Vos⁸, T. Tousseyn^9,1, D. Dierickx^1,10 Post-Transplant Lymphoproliferative Syndrome in Children and Adolescents Undergoing Transplants Hepatic and Renal: Epidemiological, Diagnostic and Therapy in a Brazilian Center F. Luisi^1,2, C. Matiuzzi², S. Martins³, N. da Silva Santos^1,2, T. Barlera^1,2, A. de Sousa^1,2, S. Abib^1,2, H. Lederman^1,2, M. Alves^1,2 NOVEL THERAPEUTICS/ALCL Discussant: Laurence Brugieres, MD Optimizing Chimeric Antigen Receptor (CAR) Engineered NK Cell- Mediated Cytotoxicity Combined With anti-CD20 or anti-CD79 therapeutic antibodies and NKTR-255 in Burkitt Lymphoma (BL) *Y. Chu¹,** M. Tian¹, M. Marcondes², W. Overwijk², D. Lee³, C. Klein⁴, M. Cairo^1,5,6,7 Immunoglobulin Subclasses of Anti-ALK Antibodies in Pediatric Anaplastic Large Cell Lymphoma* F. Knörr^1,2, L. Sabra¹, W. Wößmann¹, C. Damm-Welk¹ Variant ALK-Fusion Positive Anaplastic Large Cell Lymphoma (ALCL): A Population-Based Cohort of the NHL-BFM Study Group C. Damm-Welk1, J. Luedersen¹, U. Stadt², J. Richter³, I. Oschlies³, W. Klapper³, A. Rosenwald⁴, M. Kalinova⁵, I. Simonitsch-Klupp⁶, R. Siebert⁷, M. Zimmermann⁸, M. Alawi⁹, J. Nakel¹⁰, K. Scheinemann¹¹, F. Knörr1, ¹², A. Attarbaschi¹³, E. Kabickova¹⁴, W. Woessmann¹ Inhibition of N6-Methyladenosine (m6A) Modification as a Novel Treatment Strategy for ALK-Positive Anaplastic Large Cell Lymphoma (ALCL) L. Mun¹, V. Miano¹, N. Webster², B. Andrews², N. Han³, A. Burke⁴, I. Barberi¹, S. Turner¹ UK; ²Storm Therapeutics Ltd, Moneta Building, Babraham Research Campus, Cambridge, UK; ³Milner Therapeutics Institute, University of Cambridge, UK; Pediatric and Young Adult ALK-Negative Anaplastic Large Cell Lymphoma Genetically Differs from the Adult Counterpart J. Salmeron-Villalobos^1,2, E. James³, O. Balagué⁴, S. Mato^1,2, N. Garcia¹, M. Andres⁵; A. Attarbaschi⁶, C. Bacon⁷; A. Burke⁸; B. Lockhart⁹, L. Mussolin¹⁰, S. Pervez¹¹; V. Pillai⁹, I. Simonitsch-Klupp₁₂, M. Veening¹³, J. Verdu¹⁴; G. Wrobel¹⁵, I. Salaverria^1, S. Turner³

Sunday, October 23, 2022
7:00 AM – 1:00 PM	REGISTRATION
7:00 – 7:45 AM	BREAKFAST SYMPOSIUM – TBD
7:45 – 8:30 AM	MEET THE PROFESSORS (CHOOSE ONE SESSION)
Session 1	HEMATOPATHOLGY: WHAT’S NEW IN 2022 Rodney Miles, MD, PhD, USA
Session 2	MENTORING YOUNG INVESTIGATORS IN CHILDHOOD AND ADOLESCENT NHL: THE COG EXPERIENCE Birte Wistinghausen, MD, USA
Session 3	CLINICAL/PATHOLOGICAL SPECTRUM OF PRIMARY CUTANEOUS LYMPHOMA Ilske Oschlies, MD, Germany
Session 4	POST-TRANSPLANT LYMPHOFERATIVE DISORDER (PTLD) Thomas Gross, MD, PhD, USA
8:30 – 10:00 AM	PLENARY SESSION IX – BEST ORAL ABSTRACTS IN CHILDHOOD, ADOLESCENT AND YOUNG ADULT NHL Moderators – Mitchell S. Cairo, MD, USA, Catherine Patte, MD, France & Sherrie Perkins, MD, PhD, USA
8:30 – 8:45 AM	The Profiling of Circulating Tumor DNA in Pediatric Mature B-Cell Non-Hodgkin Lymphoma (B-NHL): A Multicenter, Prospective Clinical Study J. Wang^1, H. Guo², Y. Cai³, H. Chen³, L. Yang⁴, H. Dou⁵, X. Tian⁶, H. Xiong⁷, X. Hong⁸, C. Liang⁸, Z. Zhen¹, J. Zhu¹, S. Lu¹, F. Sun¹, J. Huang¹, Y. Zhang¹
8:45 – 9:00 AM	Pediatric Nodal Marginal Zone Lymphoma and Pediatric-Type Follicular Lymphoma Share a Common Molecular Profile J. Salmeron-Villalobos^1,2, C. Egan^3, V. Borgmann^4*, I. Müller⁴, B. Gonzalez-Farre^1,2, J. Ramis-Zaldivar^1,2, D. Nann⁴, O. Balagué^1,2, M. Lopez-Guerra^1,2, D. Colomer^1,2, I. Oschlies^5, W. Klapper⁵, S. Glaser^6, Y. Ko⁷, I. Bonzheim⁴, R. Siebert⁶, F. Fend⁴, S. Pittaluga³, E. Campo^1,2, I. Salaverria^1,2§, E. Jaffe^3§, L. Quintanilla-Martinez^4,8§
9:00 – 9:15 AM	Efficacy and Safety of Sequential Different B Cell Antigen-Targeted CAR T-Cell Therapy for Pediatric Refractory/Relapsed Burkitt Lymphoma with Secondary Central Nervous System Involvement Y. Liu¹, B. Deng², B. Hu¹,W. Zhang¹, Q. Zhu¹, Y. Liu¹, S. Wang¹, P. Zhang¹, J. Yang¹, Q. Zheng³, X.Yu³, Z. Gao⁴, C. Zhou^5, W. Han⁶, A. Chang⁷, Y. Zhang¹
9:15 – 9:30 AM	Phase 2 KEYNOTE-667 Study of Pembrolizumab (Pembro) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma (cHL) and Slow Early Response (SER) to Frontline Chemotherapy (Chemo) L. Vinti¹, Stephen Daw², C. Alvarez³, F. Fagioli⁴, A. Beishuizen⁵, G. Michel⁶, M. Moleti⁷, M. Cepelova⁸, A. Thorwarth⁹, C. Rigaud¹⁰, D. de Sabando¹¹, J. Parker¹², Y.Zhu¹³, P. Pillai¹³, A. Nahar¹³, C. Mauz-Koerholz¹⁴
9:30 – 9:45 AM	Multicenter Pilot Trial of Intrathecal Liposomal Cytarabine in CAYA with Mature De-Novo B-NHL S. Goldman¹, M. Barth², B. Shiramizu³, Q. Shi⁴, J. Hochberg⁵, L. Klejmont⁵, L. Harrison⁵, J. Basso⁵, Y. Chu⁵, H. Islam⁶, P. Gerard⁷, M. Agsalda-Garcia³, T. Shieh³, J. Oesterheld⁸, K. Heym⁹, I. Kirov¹⁰, R. Drachtman¹¹, P. Harker-Murray¹², S. Perkins¹³, R. Miles¹³, M. Cairo^5,6,14,15,16
9:45 – 10:00 AM	A Targeted Gene Expression Classifier Identifies Pediatric T-ALL Patients at High Risk for End Induction Minimal Residual Disease Positivity L. Meyer¹, Ritu P. Roy², B. Huang¹, S. Kimura³, Petri Polonen³, C. Delgado-Martin¹, T. Vincent⁴, T. Ryan⁴, B. Wood⁵, Y. Liu³, J. Zhang⁶, C. Mullighan³, T. Horton⁷, M. Loh⁸, M. Devidas⁹, E. Raetz¹⁰, R. Hayashi¹¹, S. Winter¹², K. Dunsmore¹³, S. Hunger⁴, D. Teachey⁴, M. Hermiston¹, Adam B. Olshen²
10:00 – 10:15 AM	COFFEE BREAK
10:15 – 12:00 PM	PLENARY SESSION X – ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) AND LYMPHOBLASTIC LYMPHOMA (LL) Moderators – Suzanne Turner, PhD, UK & Michelle Hermiston, MD, PhD, USA
10:15 – 10:35 AM	BRENTUXIMAB VEDOTIN IN CHILDHOOD ALCL Eric Lowe, MD, USA
10:35 – 10:55 AM	ALTERATIONS IN SIGNALING PATHWAYS LEADS TO RESISTANCE IN ALCL Suzanne Turner, PhD, UK
10:55 – 11:15 AM	NOVEL TARGETS IN T-LYMPHOBLASTIC LYMPHOMA David Teachey, MD, USA
11:15 – 11:35 AM	INNOVATIVE APPROACHES TO DETECT MDD/MRD IN ANAPLASTIC LARGE CELL LYMPHOMA AND LYMPHOBLASTIC LYMPHOMA Megan Lim, MD, PhD, USA
11:35 – 11:45 AM	Establishing the Optimal Way to Administer Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors (TKIs) in Paediatric Anaplastic Large Cell Lymphoma (ALCL) to Prevent/Delay Resistance Generation L. Hare^1,2, S. Bell¹, A. Burke², S. Turner^1,3
11:45 – 11:55 AM	Transcription and Replication Impairments Driving MYC-induced B and T Cell Lymphoblastic Lymphomas A. Sinha1, C. Foster¹, C. Sansam², P. Andrade¹, K. Foster¹, M. Malone-Perez¹, H. Harris¹, C. Sansam², J. Frazer¹
11:55 – 12:05 PM	Molecular Genetics Analysis of B-Cell Precursor Lymphoma in Pediatric and Adolescent Patients Reveals High Frequency of KMT2A Translocations I. Iaccarino¹, R. Au-Yeung², L. Padilla,³ M. Zimmermann,⁴ S. Reinke,¹ I. Oschlies,¹ G. Escherich,⁵ W. Woessmann,⁵ B. Burkhardt,³ W. Klapper
12:05 – 12:20 PM	PANEL DISCUSSION AND QUESTIONS & ANSWERS
12:20 – 12:30 PM	AWARDS SESSION BEST ORAL ABSTRACT, BEST POSTER DISCUSSION ABSTRACT & BEST POSTER ABSTRACT Award Committee – Stanton Goldman, MD, USA, and Ronit Elhasid, MD, Israel (Vice Chairs) Anthony Audino, MD, USA; M. Tezer Kutluk, MD, PhD, Turkey; and Vikki Rand, PhD, UK
12:30 – 12:45 PM	CLOSING REMARKS Mitchell S. Cairo, MD, Chair, USA

Program Agenda

Thursday, October 20, 2022

Friday, October 21, 2022

Saturday, October 22, 2022

WORLD WIDE EXPERIENCES

Discussant: Itzar Salverria, PhD

LYMPHOMA BIOLOGY

Discussant: Paul Galardy, MD

Immunology, Cell therapy, HSCT

Discussant: Birgit Burkhardt, MD, PhD

PTLD

Discussant: Thomas Gross, MD, PhD

NOVEL THERAPEUTICS/ALCL

Discussant: Laurence Brugieres, MD

Sunday, October 23, 2022